Aliskiren
Canadian Agency for Drugs and Technologies in Health
Record ID 32007000027
English, French
Authors' objectives:
The aim of this study was to summarize the available information on the use of Aliskiren (Tekturna, formerly known as Rasilez), manufactured by Novartis.
Authors' recommendations:
The prevalence of hypertension is increasing. Over the next 20 years, the number of adults with hypertension is expected to increase by about 60% to 1.5 billion adults globally. One in five Canadians, and one in three Canadians who are >45 years old have hypertension. The 2006 Canadian Hypertension Society recommendations focus on concurrent cardiovascular risk factors, patients- adherence to drug therapy, and patients' involvement in BP monitoring to ensure BP control and to reduce morbidity and mortality. Despite the availability of many well-tolerated drugs, many patients have undetected or uncontrolled hypertension. Longer-term trials that are in progress will provide information on the comparative BP efficacy, cardiovascular outcomes, and safety of aliskiren.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/
Year Published:
2006
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Hypertension
- Antihypertensive Agents
- Fumarates
- Amides
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drug and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.